Janus Henderson Group
LXEO icon

Janus Henderson Group’s Lexeo Therapeutics LXEO Stock Holding History

Janus Henderson Group’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.5M Sell
4,976,429
-533,206
-10% -$3.78M 0.01% 527
2025
Q4 		$54.7M Sell
5,509,635
-595,892
-10% -$5.44M 0.02% 393
2025
Q3 		$40.5M Buy
6,105,527
+2,421,144
+66% +$11.7M 0.02% 457
2025
Q2 		$14.8M Sell
3,684,383
-873,537
-19% -$2.87M 0.01% 629
2025
Q1 		$18.6M Buy
4,557,920
+218,666
+5% +$969K 0.01% 582
2024
Q4 		$28.5M Buy
4,339,254
+576,059
+15% +$4.54M 0.01% 511
2024
Q3 		$34M Buy
3,763,195
+599,203
+19% +$7.15M 0.02% 466
2024
Q2 		$50.7M Buy
3,163,992
+623,207
+25% +$9.05M 0.03% 382
2024
Q1 		$39.8M Buy
2,540,785
+210,047
+9% +$3.28M 0.02% 434
2023
Q4 		$31.3M Buy
+2,330,738
New +$29M 0.02% 466

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Janus Henderson Group's LXEO Position: Q1 2026 in Review

Janus Henderson Group reduced its Lexeo Therapeutics (LXEO) stake by 9.7% in Q1 2026, selling an estimated $3.78M and leaving 4,976,429 shares worth $28.5M. The position accounts for 0.01% of the portfolio, ranked #527.

Janus Henderson Group first reported a position in LXEO in Q4 2023 and has held it in 10 quarters since. The position peaked at $54.7M in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Janus Henderson Group held 4,976,429 shares of Lexeo Therapeutics worth $28.5M as of Q1 2026.
  • Janus Henderson Group sold 533,206 Lexeo Therapeutics shares in Q1 2026, an estimated $3.78M.
  • Lexeo Therapeutics made up 0.01% of Janus Henderson Group's portfolio in Q1 2026, its #527 holding.
  • Janus Henderson Group first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Janus Henderson Group's Lexeo Therapeutics position peaked at $54.7M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.